E-viri
Recenzirano
-
Barrientos, Jacqueline C
The lancet oncology, April 2018, 2018-04-00, 20180401, Letnik: 19, Številka: 4Journal Article
Selective inhibition of PI3K isoform δ-dependent signalling has direct antitumour activity and exerts pleiotropic effects in the tumour microenvironment of B-cell malignancies, inducing apoptosis and reducing proliferation.2 Idelalisib, a first-in-class drug targeting the PI3Kδ pathway, was approved for use in 2014 in the USA and the European Union after showing clinical activity in patients with relapsed or refractory chronic lymphocytic leukaemia and follicular lymphoma.3,4 Similar to other B-cell receptor inhibitors, idelalisib is administered indefinitely until disease progression or intolerable toxicities occur.
